ABVC Biopharma, Inc. reported a challenging fiscal year ending December 31, 2025, with no revenue generated compared to $509,589 in the previous year, primarily due to the absence of licensing payments. The company's gross profit also reflected this downturn, dropping from $508,826 in 2024 to zero in 2025. Operating expenses increased significantly by 37% to $7.15 million, up from $5.21 million in the prior year, driven by higher stock-based compensation expenses for consulting services and rent. This resulted in a loss from operations of $7.15 million, a 52% increase from the $4.71 million loss in 2024.
The company's net loss widened to $8.38 million, a 59% increase from the $5.26 million loss in the previous fiscal year. Other expenses, net, also increased by 81% to $1.20 million, compared to $664,334 in 2024, mainly due to the recognition of an impairment loss on an equity investment. However, interest expenses decreased by 66% to $248,787, compared to $738,541 in 2024, primarily due to the settlement of convertible notes. Basic and diluted net loss per common share was $(0.39) compared to $(0.42) in the prior year.
Operationally, ABVC Biopharma continued to advance its pipeline, with Phase II studies ongoing for Vitargus® in vitrectomy surgery in Australia and Thailand, and for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD) in Taiwan and the U.S. The company also has Phase I/II studies planned for ABV-1601 in Major Depression in Cancer Patients and ABV-1519 for Non-Small Cell Lung Cancer treatment. A significant strategic development included the acquisition of a 20% ownership stake in a property in China, intended for the development of a healthcare center. In November 2023, ABVC and its subsidiary BioLite entered into multi-year, global licensing agreements with AiBtl BioPharma Inc. for CNS drugs, receiving 23 million shares of AiBtl stock each, with potential milestone payments and royalties.
ABVC Biopharma faced challenges in maintaining its Nasdaq listing, receiving notifications regarding minimum bid price and stockholders' equity requirements. While the company successfully regained compliance with the bid price rule in May 2025, it initially failed to meet the stockholders' equity requirement, leading to a notification from Nasdaq in April 2025. However, the company subsequently demonstrated compliance based on its Q1 2025 report. As of December 31, 2025, the company's working capital deficit stood at $3.66 million, and it had 19 employees. The company's future success hinges on its ability to secure additional funding, advance its clinical trials, and establish strategic partnerships for commercialization.
About ABVC BIOPHARMA, INC.
ABVC BioPharma, Inc. is an early-stage biotechnology company focused on developing innovative botanical drugs for central nervous system and oncology diseases. With a pipeline of seven drug candidates and one medical device, ABVC targets significant unmet medical needs. The company is expanding its market presence through strategic partnerships and clinical trials in the U.S., Taiwan, and Australia, while also leveraging its GMP manufacturing capabilities for drug development.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.